Novel combination immunotherapy for pancreatic cancer: potent anti‐tumor effects with CD40 agonist and interleukin‐15 treatment

OBJECTIVES: With the poorest 5‐year survival of all cancers, improving treatment for pancreatic cancer is one of the biggest challenges in cancer research. We sought to explore the potential of combining both priming and activation of the immune system. To achieve this, we combined a CD40 agonist wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Audenaerde, Jonas RM, Marcq, Elly, von Scheidt, Bianca, Davey, Ashleigh S, Oliver, Amanda J, De Waele, Jorrit, Quatannens, Delphine, Van Loenhout, Jinthe, Pauwels, Patrick, Roeyen, Geert, Lardon, Filip, Slaney, Clare Y, Peeters, Marc, Kershaw, Michael H, Darcy, Phillip K, Smits, Evelien LJM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428816/
https://www.ncbi.nlm.nih.gov/pubmed/32821382
http://dx.doi.org/10.1002/cti2.1165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428816/
https://www.ncbi.nlm.nih.gov/pubmed/32821382
http://dx.doi.org/10.1002/cti2.1165

Ejemplares similares